Mumbai: Eris Lifesciences Limited, a leading Indian branded formulations company, announced that one of its sterile injectable manufacturing facilities located in Ahmedabad has received regulatory approval from ANVISA, Brazil’s national health authority. This facility is operated by Swiss Parenterals, a wholly owned subsidiary acquired by Eris in 2024.
This approval follows a successful inspection conducted by ANVISA in April 2025, covering both injectable manufacturing units of Swiss Parenterals. The company anticipates regulatory clearance for the second facility in the near future. Both facilities are already certified by EU-GMP and PIC/s standards and currently supply a diverse portfolio of sterile injectable products to several Latin American markets, including Mexico, Chile, Argentina, and Peru.
Company spokesperson stated that ANVISA approval marks a significant milestone in Eris’ international expansion strategy, enabling the launch of its injectable products in Brazil and facilitating comprehensive coverage across the Latin American pharmaceutical market.
Commenting on the development, Amit Bakshi, Chairman and Managing Director of Eris Lifesciences, said: “We view this approval as a strong endorsement of our operational excellence and quality standards in life-saving dosage forms such as injectables. It represents a key step forward in our strategic transformation into a company with increasing focus and leadership in complex injectables and biotechnology. Having made substantial investments to initiate this transformation last year, we are pleased to see meaningful progress and remain optimistic about further value creation in the upcoming quarters.”
About Eris Lifesciences Ltd
Founded in 2007, Eris Lifesciences is the youngest company among India’s Top-20 pharmaceutical firms. With annual branded formulations revenue exceeding INR 3,000 crore (as per AWACS), Eris maintains a diversified presence across multiple specialties and super-specialties, including Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology, and Critical Care.
Eris manufactures a wide range of prescription products across various dosage forms—oral solids, oral liquids, softgels, ointments, sprays, gels, sterile injectables, and biologics—across six state-of-the-art manufacturing facilities. These products are distributed throughout India via a robust network of approximately 5,000 stockists and over 500,000 retail pharmacies.
Over the past five years, Eris has achieved a 2.6x growth in revenue and operating profit, with FY25 revenue reaching INR 2,894 crore. The company has invested approximately INR 4,000 crore over the last three years to diversify its footprint across geographies, technologies, and therapeutic categories.
